Capricor Therapeutics (CAPR) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to Deramiocel, the company’s lead cell therapy candidate, for the potential treatment of Becker Muscular Dystrophy, BMD. This designation strengthens Capricor’s strategic position as it advances a fully integrated platform targeting the cardiac and skeletal complications of muscular dystrophy and expands the commercial potential of its lead asset.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor treatment of Becker muscular dystrophy granted orphan designation
- Roth thinks Capricor Therapeutics drug could still be approved by August 31
- Adobe reports Q2 beat, Meta invests in Scale AI: Morning Buzz
- H.C. Wainwright cautions Capricor investors to ‘calm down’ after FDA letter
- Capricor Therapeutics put volume heavy and directionally bearish